WO2013030803A1 - Choline salt of an anti - inflammatory substituted cyclobutenedione compound - Google Patents

Choline salt of an anti - inflammatory substituted cyclobutenedione compound Download PDF

Info

Publication number
WO2013030803A1
WO2013030803A1 PCT/IB2012/054502 IB2012054502W WO2013030803A1 WO 2013030803 A1 WO2013030803 A1 WO 2013030803A1 IB 2012054502 W IB2012054502 W IB 2012054502W WO 2013030803 A1 WO2013030803 A1 WO 2013030803A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
methyl
enylamino
cyclobut
propylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2012/054502
Other languages
English (en)
French (fr)
Inventor
Ameet Vijay AMBARKHANE
Arnaud MAULER
Carsten Timpe
Urs Baettig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to BR112014004963A priority Critical patent/BR112014004963A2/pt
Priority to IN2346DEN2014 priority patent/IN2014DN02346A/en
Priority to MX2014002492A priority patent/MX359259B/es
Priority to KR1020147008317A priority patent/KR102024955B1/ko
Priority to CA2846510A priority patent/CA2846510C/en
Priority to EP12780535.6A priority patent/EP2760821B1/en
Priority to PL12780535T priority patent/PL2760821T3/pl
Priority to US14/241,306 priority patent/US9018261B2/en
Priority to EA201490552A priority patent/EA201490552A1/ru
Priority to ES12780535.6T priority patent/ES2655942T3/es
Priority to SI201231173T priority patent/SI2760821T1/en
Priority to CN201280047528.3A priority patent/CN103842330B/zh
Publication of WO2013030803A1 publication Critical patent/WO2013030803A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Definitions

  • the present invention relates to a novel salt of a pharmaceutically active agent, solid pharmaceutical compositions and oral dosage forms for the delivery of said salt to patients in need thereof and the use of such solid pharmaceutical compositions and oral dosage forms.
  • Compound 6-chloro-3-[2-(1 -ethyl-propylamino)-3,4-dioxo-cyclobut-1-enylamino]-2- hydroxy-N-methoxy-N-methyl-benzenesulfonamide is a pharmaceutically active agent and acts as a CXCR2 receptor antagonist and is useful in the treatment of inflammatory, obstructive or allergic conditions and diseases, for example for the treatment of chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • Oral delivery of pharmaceutically active agents is generally the delivery route of choice, even when treating respiratory diseases, since it is convenient, relatively easy and generally painless resulting in greater patient compliance relative to other modes of delivery.
  • biological, chemical and physical barriers such as poor solubility, varying pH in the gastrointestinal tract, powerful digestive enzymes and impermeable gastrointestinal membranes make oral delivery of some
  • the present invention provides such a novel salt form of 6-chloro-3-[2-(1-ethyl- propylamino)-3,4-dioxo-cyclobut-1 -enylamino]-2-hydroxy-N-methoxy-N-methyl- benzenesulfonamide and formulation of same which solve the above problems or at least provide a useful alternative to the known salts and formulations of this compound.
  • the present invention relates to the choline salt of 6-chloro-3-[2-(1- ethyl-propylamino)-3,4-dioxo-cyclobut-1 -enylamino]-2-hydroxy-N-methoxy-N-methyl- benzenesulfonamide of formula II
  • the invention relates to a solid pharmaceutical composition
  • a solid pharmaceutical composition comprising
  • acidic agents can also be used to adjust the pH of the alkalizing agent as long as the alkalizing agent as a whole raises the pH of the micro- environment in the hydrated formulation to greater than about the pKa of 6-chloro-3- [2-(1 -ethyl-propylamino)-3,4-dioxo-cyclobut-1 -enylamino]-2-hydroxy-N-methoxy-N- methyl-benzenesulfonamide.
  • Suitable alkalizing agents include but are not limited to organic and inorganic basic compounds of a wide range of aqueous solubilities and molecular weights and mixtures thereof.
  • inorganic basic salts include ammonium hydroxide, alkali metal salts, alkaline earth metal salts such as magnesium oxide, magnesium hydroxide, calcium hydroxide, sodium hydroxide, potassium hydroxide, aluminium hydroxide, potassium carbonate, sodium
  • an alkalizing agent is selected from magnesium oxide, calcium carbonate, calcium phosphate and combinations thereof. More particularly, the alkalizing agent is magnesium oxide.
  • precipitation inhibiting agent refers to salts, ions, carbohydrates, surfactants, amino acids, polymers and other compounds which, when present in solution, decrease the precipitation (crystallization) of 6-chloro-3-[2- (1-ethyl-propylamino)-3,4-dioxo-cyclobut-1 -enylamino]-2-hydroxy-N-methoxy-N- methyl-benzenesulfonamide.
  • precipitation inhibitors include but are not limited to polyvinyl pyrrolidone, for example those products known as PVP K30, PVP K29/32 and PVPP XL, and hydroxy propyl methyl cellulose (HPMC), for example those products known as PHARMACOAT® low viscous hypromellose-based water- soluble film coating agent.
  • polyvinyl pyrrolidone for example those products known as PVP K30, PVP K29/32 and PVPP XL
  • HPMC hydroxy propyl methyl cellulose
  • additional pharmaceutically acceptable carrier refers to conventional pharmaceutical carriers, such as disintegrants, diluents, lubricants, glidants and binders which are known to a person skilled in the galenic art, and which are added to the composition in addition to the alkalizing agent(s) and the
  • disintegrants such as croscarmellose sodium, sodium starch glycolate and crospovidone may be used as additional pharmaceutically acceptable carriers ⁇ .
  • an additional pharmaceutically acceptable carrier is selected from disintegrants, diluents, lubricants, glidants and binders. More particularly, the pharmaceutically acceptable carrier is selected from croscarmellose sodium, mannitol, microcrystalline cellulose, magnesium stearate and colloidal silicon dioxide.
  • oral dosage form refers to physically discrete units suitable as unitary dosages for humans and other mammals, each unit containing a predetermined quantity of a therapeutic agent in association with one or more pharmaceutically acceptable carrier.
  • Well-known oral dosage forms are for example tablets, capsules and caplets.
  • the present invention provides a novel salt of 6-chloro-3-[2-(1-ethyl- propylamino)-3,4-dioxo-cyclobut-1 -enylamino]-2-hydroxy-N-methoxy-N-methyl- benzenesulfonamide, namely 6-chloro-3-[2-(1 -ethyl-propylamino)-3,4-dioxo-cyclobut- 1 -enylamino]-2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide choline of formula II.
  • the choline salt of 6-chloro-3-[2-(1 -ethyl-propylamino)- 3,4-dioxo-cyclobut-1 -enylamino]-2-hydroxy-N-methoxy-N-methyl- benzenesulfonamide has superior solubility in simulated gastric fluid.
  • the solubility of the free acid is 0.001 mg/ml in simulated gastric fluid at pH 1.2
  • the solubility of the choline salt is 8.018 mg/ml.
  • solubility of the choline salt in simulated gastric fluid is also significantly improved compared to other salts of 6-chloro-3-[2-(1 -ethyl-propylamino)-3,4-dioxo-cyclobut-1-enylamino]-2-hydroxy-N- methoxy-N-methyl-benzenesulfonamide such as sodium, calcium, N,N-dimethyl-2- aminoethanol and N ⁇ (2 ⁇ hydroxyethy!pyrroiidine salts.
  • the hygroscopicity of the choline salt is much reduced compared with the free acid.
  • the amount of water absorbed by the free acid is 2.4% and 2.8% by weight after 1 day at 80% and 92% humidity, respectively, and the amount of water absorbed by the choline salt is 0.7% and 0.6% by weight after 1 day at 80% and 92% humidity, respectively.
  • the choline salt has also a much improved dissolution rate at pH 1 and oral exposure when dosed at 10mg/kg to male SPRAGUE DAWLEY® rats compared to the free acid form.
  • the choline salt of 6-chloro-3-[2-(1-ethyl-propylamino)-3,4-dioxo-cyclobut-1- enylamino]-2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide has good solubility in gastric acidic conditions in the stomach
  • the choline salt of 6-chloro-3-[2-(1-ethyl- propylamino)-3,4-dioxo-cyclobut-1 -enylamino]-2-hydroxy-N-methoxy-N-methyl- benzenesulfonamide readily converts in gastric acidic conditions into the free acid form which is poorly soluble.
  • the present invention provides a solid pharmaceutical composition of 6-chloro-3-[2-(1 -ethyl-propylamino)-3,4-dioxo-cyclobut-1-enylamino]- 2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide choline.
  • composition comprises
  • this composition has an improved dissolution rate and an improved bioavailability as measured as AUC, mean C ma x and lower inter-animal variability denoted by the %CV (see Example 7, Table 1 , Figure 1 ).
  • the alkalizing agent is selected from magnesium oxide, calcium carbonate, calcium phosphate and combinations thereof. Particularly, the alkalizing agent is magnesium oxide.
  • the precipitation inhibiting agent is selected from polyvinylpyrrolidone and
  • the precipitation inhibiting agent is polyvinylpyrrolidone. More particularly, polyvinylpyrrolidone is selected from products known as PVP K30, PVP K29/32 and PVPP XL, even more particularly PVP K30.
  • the amount of alkalizing agent is in the range from about 5% to about 30% by weight of the total weight of solid pharmaceutical composition, particularly the amount of alkalizing agent is in the range from about 10% to about 20% by weight of the total weight of solid pharmaceutical composition, more particularly in the range from about 10% to about 15% by weight.
  • the amount of precipitation inhibiting agent is in the range from about 8% to about 20% by weight of the total weight of solid pharmaceutical composition, particularly in the range from about 10% to about 15% by weight.
  • the additional pharmaceutically acceptable carrier is selected from disintegrants, diluents, lubricants, glidants and binders, or a mixture thereof.
  • the invention in one embodiment (vi) of the second aspect or embodiments (i) to (v) of the second aspect, relates to a solid pharmaceutical composition
  • a solid pharmaceutical composition comprising a) choline salt of 6-chloro-3-[2-(1 -ethyl-propylamino)-3,4-dioxo-cyclobut-1 - enylamino]-2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide;
  • the composition further comprises microcrystalline cellulose, magnesium stearate and colloidal silicon dioxide.
  • the present invention relates to an oral dosage form comprising the composition according to the second aspect or embodiments (i)-(vii) of the second aspect.
  • the amount of the choline salt of 6-chloro-3- [2-(1 -ethyl-propylamino)-3,4-dioxo-cyclobut-1 -enylamino]-2-hydroxy-N-methoxy-N- methyl-benzenesulfonamide is from about 5 to about 100 mg on a dry basis calculated as the free acid.
  • the amount of the choline salt of 6-chloro-3- [2-(1 -ethyl-propylamino)-3,4-dioxo-cyclobut-1 -enylamino]-2-hydroxy-N-methoxy-N- methyl-benzenesulfonamide is about 75 mg on a dry basis calculated as the free acid.
  • the amount of the choline salt of 6- chloro-3-[2-(1 -ethyl-propylamino)-3,4-dioxo-cyclobut-1 -enylamino]-2-hydroxy-N- methoxy-N-methyl-benzenesulfonamide is about 25 mg on a dry basis calculated as the free acid.
  • the amount of the choline salt of 6- chloro-3-[2-(1 -ethyl-propylamino)-3,4-dioxo-cyclobut-1 -enylamino]-2-hydroxy-N- methoxy-N-methyl-benzenesulfonamide is about 5 mg on a dry basis calculated as the free acid.
  • the dosage form is selected from a tablet, capsule and caplet, particularly a capsule.
  • Such capsules may be prepared by a conventional blending process, for example in a diffusion blender and using appropriate sieving steps to enable a homogenous distribution of the ingredients.
  • the particle sizes of carriers should not differ too much from the particle size of the choline salt of 6-chloro-3-[2-(1 -ethyl-propylamino)-3,4-dioxo-cyclobut-1 - enylamino]-2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide to avoid segregation during blending.
  • the final blend can be filled manually or an automated capsule filling machine into hard gelatin, HPMC, starch or pullulan capsules.
  • the present invention relates to a composition or oral dosage form according to the second and third aspect, respectively, for use in medicine, particularly for use in the treatment of conditions and diseases mediated by CXCR2, for example inflammatory, obstructive or allergic conditions and diseases, particularly chronic obstructive pulmonary airways disease (COPD), including chronic bronchitis or dyspnea associated therewith, emphysema, bronchiolitis obliterans syndrome and severe asthma.
  • COPD chronic obstructive pulmonary airways disease
  • the present invention relates to a method of treating conditions and diseases mediated by CXCR2, for example inflammatory or allergic conditions and diseases, particularly chronic obstructive pulmonary airways disease (COPD), including chronic bronchitis or dyspnea associated therewith, emphysema, bronchiolitis obliterans syndrome and severe asthma, comprising administering to a person or mammal an effective amount of a composition or an oral dosage form according to the second and third aspect, respectively.
  • COPD chronic obstructive pulmonary airways disease
  • Example 1 Small scale preparation of choline salt of 6-chloro-3-[2-(1 -ethyl- propylamino)-3,4-dioxo-cyclobut-1 -enylamino]-2-hydroxy-N-methoxy-N-methyl- benzenesulfonamide
  • Isopropanol (64.1 kg, 82 litres) was then added over 30 minutes and the whole cooled to 55 ⁇ 2 ° C. Seed crystals of 6-chloro-3- [2-(1 -ethyl-propylamino)-3,4-dioxo-cyclobut-1 -enylamino]-2-hydroxy-N-methoxy-N- methyl-benzenesulfonamide choline (0.016 kg) were added and the suspension stirred at 55 ⁇ 2 ° C before cooling down to 0 ⁇ 2 ° C over 2 hours. The suspension was stirred for a further 2 hours before being centrifuged, washed with isopropanol (52.1 kg, 67 litres), filtered and the obtained crystals (25.4 kg) dried.
  • Example 3 63 mg capsule (calculated as free acid) of choline salt of 6-chloro-3- [2-(1 -ethyl -propylamino)-3, 4-dioxo-cyclobut-1 -enylamino]-2 -hydroxy-N- methoxy-N -methyl-benzenesulfonamide
  • a pharmaceutical composition was prepared in the manner described in Example 1 from the ingredients listed in the following table and filled into capsules:
  • Example 4 75 mg capsule (calculated as free acid) of choline salt of 6-chloro-3- [2-(1 -ethyl -propylamino)-3, 4-dioxo-cyclobut-1 -enylamino]-2 -hydroxy-N- methoxy-N -methyl-benzenesulfonamide
  • a pharmaceutical composition was prepared in the manner described in Example 1 from the ingredients listed in the following table and filled into capsules:
  • Example 5 25 mg capsule (calculated as free acid) of choline salt of 6-chloro-3- [2-(1 -ethyl -propylamino)-3, 4-dioxo-cyclobut-1 -enylamino]-2 -hydroxy-N- methoxy-N -methyl -benzenesulfonamide
  • Example 6 5 mg capsule (calculated as free acid) of choline salt of 6-chloro-3- [2-(1 -ethyl -propylamino)-3, 4-dioxo-cyclobut-1 -enylamino]-2 -hydroxy-N- methoxy-N -methyl -benzenesulfonamide
  • Example 7 Pharmacokinetic studies of the choline salt of 6-chloro-3-[2-(1 - ethyl-propylamino)-3,4-dioxo-cyclobut-1 -enylamino]-2-hydroxy-N-methoxy-N- methyl-benzenesulfonamide
  • the dogs were pretreated with pentagastrine (6 ⁇ g/kg) in order to lower the pH in the stomach and mimic more acidic conditions in humans.
  • the mean dose normalized AUCIast of Form 1 was 1.7 and 1.3 times higher than the one of Form 2 and 3, respectively, with no impact on the T max .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PCT/IB2012/054502 2011-09-02 2012-08-31 Choline salt of an anti - inflammatory substituted cyclobutenedione compound Ceased WO2013030803A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
BR112014004963A BR112014004963A2 (pt) 2011-09-02 2012-08-31 sal de colina do composto anti-inflamatório ciclobutanodiona substituído
IN2346DEN2014 IN2014DN02346A (enExample) 2011-09-02 2012-08-31
MX2014002492A MX359259B (es) 2011-09-02 2012-08-31 Sal de colina de un compuesto anti - inflamatorio de ciclobutenodiona sustituida.
KR1020147008317A KR102024955B1 (ko) 2011-09-02 2012-08-31 치환된 시클로부텐디온 항염 화합물의 콜린 염
CA2846510A CA2846510C (en) 2011-09-02 2012-08-31 Choline salt of an anti - inflammatory substituted cyclobutenedione compound
EP12780535.6A EP2760821B1 (en) 2011-09-02 2012-08-31 Choline salt of an anti-inflammatory substituted cyclobutenedione compound
PL12780535T PL2760821T3 (pl) 2011-09-02 2012-08-31 Sól cholinowa przeciwzapalnego związku podstawionego cyklobutenodionem
US14/241,306 US9018261B2 (en) 2011-09-02 2012-08-31 Choline salt of an anti-inflammatory substituted cyclobutenedione compound
EA201490552A EA201490552A1 (ru) 2011-09-02 2012-08-31 Холиновая соль замещенного циклобутендиона, обладающая противовоспалительной способностью
ES12780535.6T ES2655942T3 (es) 2011-09-02 2012-08-31 Sal de colina de un compuesto anti-inflamatorio de ciclobutenodiona sustituida
SI201231173T SI2760821T1 (en) 2011-09-02 2012-08-31 A salt salt of an anti-inflammatory substituted cyclobutenedione compound
CN201280047528.3A CN103842330B (zh) 2011-09-02 2012-08-31 抗炎的取代的环丁烯二酮化合物的胆碱盐

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161530516P 2011-09-02 2011-09-02
US61/530,516 2011-09-02

Publications (1)

Publication Number Publication Date
WO2013030803A1 true WO2013030803A1 (en) 2013-03-07

Family

ID=47116123

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/054502 Ceased WO2013030803A1 (en) 2011-09-02 2012-08-31 Choline salt of an anti - inflammatory substituted cyclobutenedione compound

Country Status (17)

Country Link
US (1) US9018261B2 (enExample)
EP (2) EP2760821B1 (enExample)
JP (3) JP2014529621A (enExample)
KR (1) KR102024955B1 (enExample)
CN (1) CN103842330B (enExample)
BR (1) BR112014004963A2 (enExample)
CA (1) CA2846510C (enExample)
EA (1) EA201490552A1 (enExample)
ES (1) ES2655942T3 (enExample)
HU (1) HUE035751T2 (enExample)
IN (1) IN2014DN02346A (enExample)
MX (1) MX359259B (enExample)
NO (1) NO2679622T3 (enExample)
PL (1) PL2760821T3 (enExample)
PT (1) PT2760821T (enExample)
SI (1) SI2760821T1 (enExample)
WO (1) WO2013030803A1 (enExample)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
US9809581B2 (en) 2015-11-19 2017-11-07 Chemocentryx, Inc. Inhibitors of CXCR2
US9834545B2 (en) 2015-11-19 2017-12-05 Chemocentryx, Inc. Modulators of chemokine receptors
WO2019099838A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
WO2020012337A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2021123996A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
US11207294B2 (en) 2018-01-08 2021-12-28 Chemocentryx, Inc. Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022215011A1 (en) 2021-04-07 2022-10-13 Novartis Ag USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
WO2022243846A1 (en) 2021-05-18 2022-11-24 Novartis Ag Combination therapies

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015613A1 (en) 2008-08-04 2010-02-11 Novartis Ag Organic compounds

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506252A (en) 1993-11-17 1996-04-09 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
JPH10509145A (ja) 1994-11-16 1998-09-08 アメリカン・ホーム・プロダクツ・コーポレイション ジアミノシクロブテン−３，４−ジオン
WO1998033763A1 (en) 1997-01-30 1998-08-06 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
US5840764A (en) 1997-01-30 1998-11-24 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
US6166050A (en) 1998-12-14 2000-12-26 American Home Products Corporation 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4
FR2815345B1 (fr) 2000-10-12 2002-12-13 Servier Lab Nouveaux derives de cyclobutene-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0028844D0 (en) 2000-11-27 2001-01-10 Celltech Chiroscience Ltd Chemical compounds
US20040132694A1 (en) 2001-01-16 2004-07-08 Palovich Michael R. Il-8 receptor antagonists
US20040048897A1 (en) 2001-01-16 2004-03-11 Mccleland Brent Il-8 receptor antagonists
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
WO2002062761A1 (en) 2001-02-07 2002-08-15 Abbott Laboratories Aminal diones as potassium channel openers
KR20030088044A (ko) 2001-03-30 2003-11-15 스미스클라인 비참 코포레이션 페놀-함유 화합물의 합성 방법
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
PT1818325E (pt) 2001-04-16 2010-05-12 Schering Corp Ciclobuteno-1,2-dionas 3,4-di-substituídas como ligandos de receptor de quimoquina cxc
WO2003000245A1 (en) 2001-06-22 2003-01-03 Poseidon Pharmaceuticals A/S Compounds for use in disorders associated with mast cell or basophil activity
BR0308739A (pt) 2002-03-18 2005-01-11 Schering Corp Tratamentos em combinação para doenças mediadas por quimiocina
WO2005004915A2 (en) * 2003-07-09 2005-01-20 Boehringer Ingelheim International Gmbh Compositions comprising meloxicam
DE602005022986D1 (de) 2004-01-30 2010-09-30 Schering Corp Kristalline polymorphe eines cxc-chemokinrezeptorliganden
WO2005076987A2 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
US7635694B2 (en) 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
GB0407908D0 (en) * 2004-04-07 2004-05-12 Univ York Ionic liquids
DE102004046492A1 (de) 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE602004021404D1 (de) 2004-12-23 2009-07-16 Gpc Biotech Ag Quadratsäurederivate mit antiproliferativer Wirkung
DE102005001053A1 (de) 2005-01-07 2006-07-20 Merck Patent Gmbh Quadratsäurederivate
KR20070104460A (ko) 2005-02-10 2007-10-25 와커 헤미 아게 보호된 이소시아네이트기를 가지는 입자를 함유하는 래커
US7566718B2 (en) 2005-02-16 2009-07-28 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
DE102005035742A1 (de) 2005-07-29 2007-02-01 Merck Patent Gmbh Quadratsäurederivate II
DE102005035741A1 (de) 2005-07-29 2007-02-08 Merck Patent Gmbh Quadratsäurederivate
KR20090028811A (ko) 2006-07-07 2009-03-19 쉐링 코포레이션 Ｃｘｃ-케모카인 수용체 리간드로서의 3,4-이치환된 사이클로부텐-1,2-디온
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
MX2009009540A (es) 2007-03-07 2009-09-16 Alantos Pharm Holding Inhibidores de metaloproteasa que contienen una porcion heterociclica.
KR20100031718A (ko) 2007-06-06 2010-03-24 노파르티스 아게 항-염증성 치환된 시클로부텐디온 화합물
WO2009005801A1 (en) 2007-07-03 2009-01-08 Schering Corporation Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
EP2181102A1 (en) 2007-07-05 2010-05-05 Schering Corporation Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
WO2009012375A2 (en) 2007-07-19 2009-01-22 Wyeth Squarate kinase inhibitors
US20110009482A1 (en) 2007-12-04 2011-01-13 Schering Corporation Methods of treating copd
PL2444120T3 (pl) 2007-12-10 2018-02-28 Novartis Ag Spirocyklicze analogi amiloridu jako blokery ENac
JP2011526888A (ja) * 2008-07-01 2011-10-20 ザ・ジョンズ・ホプキンス・ユニバーシティ 治療薬を標的送達するための経口速溶性薄膜
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
WO2010017051A1 (en) 2008-08-04 2010-02-11 Merck Serono S.A. Novel phenylamino isonicotinamide compounds
CL2009002073A1 (es) * 2008-11-14 2010-12-24 Portola Pharm Inc Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares.
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
WO2010091543A1 (en) 2009-02-10 2010-08-19 Merck Sharp & Dohme Corp. Novel hydrazino-cyclobut-3-ene-1, 2-dione derivatives as cxcr2 antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015613A1 (en) 2008-08-04 2010-02-11 Novartis Ag Organic compounds

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
US10988464B2 (en) 2015-11-19 2021-04-27 Chemocentryx, Inc. Modulators of chemokine receptors
US11040960B2 (en) 2015-11-19 2021-06-22 Chemocentryx, Inc. Inhibitors of CXCR2
US10336736B2 (en) 2015-11-19 2019-07-02 Chemocentryx, Inc. Modulators of chemokine receptors
US10370363B2 (en) 2015-11-19 2019-08-06 Chemocentryx, Inc. Inhibitors of CXCR2
US11945805B2 (en) 2015-11-19 2024-04-02 Chemocentryx, Inc Inhibitors of CXCR2
US11820759B2 (en) 2015-11-19 2023-11-21 Chemocentryx, Inc. Modulators of chemokine receptors
US9809581B2 (en) 2015-11-19 2017-11-07 Chemocentryx, Inc. Inhibitors of CXCR2
US9834545B2 (en) 2015-11-19 2017-12-05 Chemocentryx, Inc. Modulators of chemokine receptors
WO2019099838A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
US11684606B2 (en) 2018-01-08 2023-06-27 Chemocentryx, Inc. Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2
US11207294B2 (en) 2018-01-08 2021-12-28 Chemocentryx, Inc. Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2
WO2020012337A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2021123996A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022215011A1 (en) 2021-04-07 2022-10-13 Novartis Ag USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
WO2022243846A1 (en) 2021-05-18 2022-11-24 Novartis Ag Combination therapies

Also Published As

Publication number Publication date
EP2760821A1 (en) 2014-08-06
MX359259B (es) 2018-09-20
BR112014004963A2 (pt) 2017-03-21
EP3287438A1 (en) 2018-02-28
KR102024955B1 (ko) 2019-09-24
US20140206768A1 (en) 2014-07-24
KR20140059264A (ko) 2014-05-15
CN103842330B (zh) 2016-10-19
EA201490552A1 (ru) 2014-11-28
US9018261B2 (en) 2015-04-28
CA2846510A1 (en) 2013-03-07
HUE035751T2 (hu) 2018-08-28
JP2019001787A (ja) 2019-01-10
SI2760821T1 (en) 2018-02-28
ES2655942T3 (es) 2018-02-22
JP2017025081A (ja) 2017-02-02
PT2760821T (pt) 2018-01-11
IN2014DN02346A (enExample) 2015-05-15
MX2014002492A (es) 2014-05-28
CA2846510C (en) 2019-10-22
JP2014529621A (ja) 2014-11-13
NO2679622T3 (enExample) 2018-01-20
EP2760821B1 (en) 2017-10-11
PL2760821T3 (pl) 2018-04-30
JP6612200B2 (ja) 2019-11-27
CN103842330A (zh) 2014-06-04

Similar Documents

Publication Publication Date Title
CA2846510C (en) Choline salt of an anti - inflammatory substituted cyclobutenedione compound
US20250144112A1 (en) Suspension for oral administration comprising amorphous tolvaptan
US8883777B2 (en) Compositions controlling pH range of release and/or release rate
KR101257918B1 (ko) 콜린 알포세레이트 또는 이의 약학적으로 허용되는 염을 포함하는 서방형 약학 조성물 및 이의 제조방법
WO2013012199A1 (en) Capsule formulation comprising montelukast and levocetirizine
TR201807978T4 (tr) Levosetirizin veya bunun farmasötik olarak kabul edilebilen bir tuzunu ve montelukast veya bunun farmasötik olarak kabul edilebilen bir tuzunu içeren oral uygulama için stabil farmasötik formülasyon.
EP2540318A1 (en) Sustained-release solid preparation for oral use
WO2015142178A1 (en) Bile acid composition with enhanced solubility
US9968607B2 (en) Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
AU2023227540A1 (en) Therapeutic compounds, formulations, and use thereof
EP1617826B1 (en) The dispersible alendronate microparticle formulation
AU2017251803B2 (en) Choline salt of an anti-inflammatory substituted cyclobutenedione compound
WO2015069203A1 (en) Capsule comprising rupatadine fumarate and montelukast sodium
AU2012303675A1 (en) Choline salt of an anti - inflammatory substituted cyclobutenedione compound
US20250170065A1 (en) Therapeutic compounds, formulations, and use thereof
WO2013132512A1 (en) "pharmaceutical composition of raloxifene hydrochloride"
US20110160213A1 (en) Pharmaceutical compositions for the treatment of inflammatory and allergic disorders
KR20240155526A (ko) 엔잘루타마이드를 포함하는 무정형 고체 분산체, 그를 포함하는 경구 투여용 약제학적 제제
EP2705839A1 (en) Pharmaceutical composition comprising lacidipine and process of preparation
WO2015063669A1 (en) Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12780535

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2012780535

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012780535

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2846510

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14241306

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2014527801

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/002492

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2012303675

Country of ref document: AU

Date of ref document: 20120831

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20147008317

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201490552

Country of ref document: EA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014004963

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014004963

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140228